Clinical trial
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
NCT00182767 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00182767 |
|---|---|
| Title | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer |
| Official title | A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | ixabepilone, pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 45 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2012 |
| Completion | May 1, 2014 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: